News
-
-
-
COMMUNIQUÉ DE PRESSE
Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market
Laxxon Medical announces development program for LXM.2, a 3D printed oral GLP-1 receptor agonist for obesity treatment, offering an alternative to injections. Utilizes SPID® platform technology for enhanced bioavailability -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Laxxon Medical to Participate in the World Orphan Drug Congress USA 2024
Laxxon Medical to participate in World Orphan Drug Congress USA 2024. Dr. Catherine Gatza to represent the Company at the event in Boston, Massachusetts. Company leveraging SPID®-Technology for pharmaceutical advancements -